small molecule

INOMAX

NITRIC OXIDE

Loss of exclusivityJuly 2031latest FDA-listed patent expiry
CompanyMALLINCKRODT PHARMACEUTICALS IRELAND LTD

Drug detail

Brand nameINOMAX
Active ingredientNITRIC OXIDE
Strength100PPM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formGAS
RouteINHALATION
ModalitySmall molecule
FDA approvalDecember 1999
Marketing statusDISCN

Listed patents

PatentExpiresType
8291904*PEDJuly 2031
8573210*PEDJuly 2031
8573209*PEDJuly 2031
8776794*PEDJuly 2031
8776795*PEDJuly 2031
8573209January 2031product
8776795January 2031product
8776794January 2031product
8291904January 2031product
8573210January 2031product
8282966*PEDDecember 2029
8293284*PEDDecember 2029
8431163*PEDDecember 2029
8795741*PEDDecember 2029
8846112*PEDDecember 2029
8293284June 2029use U-1286
8431163June 2029use U-1286
8795741June 2029use U-1286
8282966June 2029use U-1286
8846112June 2029use U-1286

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INOMAX patent cliff — loss of exclusivity July 2031 | CliffBio